NCT07211958 - Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | Biotech Hunter

Enrollment

468

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

January 31, 2031

Conditions

Acute Myeloid Leukemias

Interventions

DRUG

Revumenib

Participants will receive revumenib orally.

DRUG

Placebo

Participants will receive placebo (non-active agent) orally.

DRUG

Intensive Chemotherapy Regimen

Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.